DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

10 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

27 2 2023 15:01:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

22 2 2023 15:33:24 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

15 2 2023 15:01:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

25 1 2023 07:00:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

09 1 2023 07:00:44 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

05 12 2022 06:00:41 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 11 2022 15:01:44 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

01 11 2022 07:00:02 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

24 10 2022 15:30:04 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

19 10 2022 20:19:42 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock

18 10 2022 15:40:50 提供 Nasdaq GlobeNewswire

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

03 10 2022 07:00:39 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

31 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

08 8 2022 15:01:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

31 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

05 5 2022 15:01:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

02 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors

15 3 2022 15:30:28 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)

09 3 2022 07:00:01 提供 Nasdaq GlobeNewswire